Annual EBITDA
-$163.46 M
-$64.73 M-65.55%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$163.46 million, with the most recent change of -$64.73 million (-65.55%) on 31 December 2023. During the last 3 years, it has fallen by -$122.37 million (-297.76%). LXRX annual EBITDA is now -210.11% below its all-time high of $148.45 million, reached on 31 December 2019.LXRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$60.12 M
-$9.04 M-17.71%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$60.12 million, with the most recent change of -$9.04 million (-17.71%) on 30 September 2024. Over the past year, it has dropped by -$13.65 million (-29.37%). LXRX quarterly EBITDA is now -126.58% below its all-time high of $226.18 million, reached on 30 September 2019.LXRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$198.69 M
-$13.65 M-7.38%
30 September 2024
Summary:
Lexicon Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$198.69 million, with the most recent change of -$13.65 million (-7.38%) on 30 September 2024. Over the past year, it has dropped by -$50.13 million (-33.74%). LXRX TTM EBITDA is now -208.69% below its all-time high of $182.81 million, reached on 30 September 2019.LXRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.5% | -29.4% | -33.7% |
| 3 y3 years | -297.8% | -163.1% | -199.1% |
| 5 y5 years | -70.1% | -126.6% | -208.7% |
LXRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -297.8% | at low | -168.2% | at low | -199.1% | at low |
| 5 y | 5 years | -210.1% | at low | -126.6% | +4.6% | -208.7% | at low |
| alltime | all time | -210.1% | at low | -126.6% | +4.6% | -208.7% | at low |
Lexicon Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$60.12 M(+17.7%) | -$198.69 M(+7.4%) |
| June 2024 | - | -$51.08 M(+18.0%) | -$185.05 M(+4.7%) |
| Mar 2024 | - | -$43.30 M(-2.0%) | -$176.77 M(+8.1%) |
| Dec 2023 | -$163.46 M(+65.6%) | -$44.19 M(-4.9%) | -$163.46 M(+10.0%) |
| Sept 2023 | - | -$46.48 M(+8.6%) | -$148.56 M(+19.3%) |
| June 2023 | - | -$42.80 M(+42.7%) | -$124.50 M(+18.0%) |
| Mar 2023 | - | -$30.00 M(+2.4%) | -$105.48 M(+6.8%) |
| Dec 2022 | -$98.74 M(+13.9%) | -$29.29 M(+30.7%) | -$98.74 M(+4.3%) |
| Sept 2022 | - | -$22.41 M(-5.7%) | -$94.65 M(-0.5%) |
| June 2022 | - | -$23.78 M(+2.2%) | -$95.09 M(+6.6%) |
| Mar 2022 | - | -$23.26 M(-7.7%) | -$89.17 M(+2.9%) |
| Dec 2021 | -$86.66 M(+110.9%) | -$25.20 M(+10.3%) | -$86.66 M(+30.4%) |
| Sept 2021 | - | -$22.85 M(+28.0%) | -$66.44 M(-251.3%) |
| June 2021 | - | -$17.86 M(-14.0%) | $43.91 M(-3541.5%) |
| Mar 2021 | - | -$20.75 M(+316.7%) | -$1.28 M(-96.9%) |
| Dec 2020 | -$41.10 M(-127.7%) | -$4.98 M(-105.7%) | -$41.10 M(-49.3%) |
| Sept 2020 | - | $87.50 M(-238.8%) | -$81.13 M(-241.0%) |
| June 2020 | - | -$63.05 M(+4.1%) | $57.55 M(-44.5%) |
| Mar 2020 | - | -$60.57 M(+34.6%) | $103.65 M(-30.2%) |
| Dec 2019 | $148.45 M(-254.5%) | -$45.01 M(-119.9%) | $148.45 M(-18.8%) |
| Sept 2019 | - | $226.18 M(-1434.9%) | $182.81 M(-383.0%) |
| June 2019 | - | -$16.94 M(+7.4%) | -$64.59 M(-15.1%) |
| Mar 2019 | - | -$15.78 M(+48.2%) | -$76.08 M(-20.8%) |
| Dec 2018 | -$96.09 M(-23.3%) | -$10.65 M(-49.8%) | -$96.09 M(-11.6%) |
| Sept 2018 | - | -$21.23 M(-25.3%) | -$108.69 M(-6.0%) |
| June 2018 | - | -$28.43 M(-20.5%) | -$115.64 M(-3.4%) |
| Mar 2018 | - | -$35.78 M(+53.9%) | -$119.73 M(-4.4%) |
| Dec 2017 | -$125.27 M(+2.0%) | -$23.24 M(-17.5%) | -$125.27 M(+2.4%) |
| Sept 2017 | - | -$28.18 M(-13.4%) | -$122.32 M(-4.4%) |
| June 2017 | - | -$32.53 M(-21.3%) | -$128.00 M(-2.6%) |
| Mar 2017 | - | -$41.32 M(+103.6%) | -$131.43 M(+7.0%) |
| Dec 2016 | -$122.82 M(-4538.8%) | -$20.29 M(-40.1%) | -$122.82 M(+775.1%) |
| Sept 2016 | - | -$33.86 M(-5.8%) | -$14.04 M(+2.4%) |
| June 2016 | - | -$35.96 M(+9.9%) | -$13.71 M(+249.2%) |
| Mar 2016 | - | -$32.71 M(-137.0%) | -$3.93 M(-241.9%) |
| Dec 2015 | $2.77 M(-102.9%) | $88.49 M(-363.9%) | $2.77 M(-103.2%) |
| Sept 2015 | - | -$33.53 M(+28.1%) | -$87.63 M(-6.4%) |
| June 2015 | - | -$26.17 M(+0.6%) | -$93.62 M(+1.2%) |
| Mar 2015 | - | -$26.02 M(+1264.4%) | -$92.47 M(-3.9%) |
| Dec 2014 | -$96.18 M(-3.1%) | -$1.91 M(-95.2%) | -$96.18 M(-13.0%) |
| Sept 2014 | - | -$39.52 M(+58.0%) | -$110.54 M(+8.8%) |
| June 2014 | - | -$25.02 M(-15.9%) | -$101.61 M(-2.6%) |
| Mar 2014 | - | -$29.73 M(+82.8%) | -$104.35 M(+5.1%) |
| Dec 2013 | -$99.29 M(-4.4%) | -$16.27 M(-46.8%) | -$99.29 M(-6.7%) |
| Sept 2013 | - | -$30.59 M(+10.2%) | -$106.46 M(+2.5%) |
| June 2013 | - | -$27.76 M(+12.5%) | -$103.83 M(+3.4%) |
| Mar 2013 | - | -$24.68 M(+5.3%) | -$100.38 M(-3.4%) |
| Dec 2012 | -$103.91 M | -$23.44 M(-16.2%) | -$103.91 M(-7.7%) |
| Sept 2012 | - | -$27.96 M(+15.0%) | -$112.63 M(+3.3%) |
| June 2012 | - | -$24.31 M(-13.8%) | -$109.03 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$28.21 M(-12.3%) | -$109.39 M(+0.3%) |
| Dec 2011 | -$108.80 M(+16.1%) | -$32.16 M(+32.0%) | -$109.01 M(+11.3%) |
| Sept 2011 | - | -$24.36 M(-1.2%) | -$97.91 M(-1.2%) |
| June 2011 | - | -$24.66 M(-11.4%) | -$99.12 M(+2.0%) |
| Mar 2011 | - | -$27.83 M(+32.1%) | -$97.16 M(+4.6%) |
| Dec 2010 | -$93.69 M(+11.1%) | -$21.06 M(-17.6%) | -$92.92 M(+0.5%) |
| Sept 2010 | - | -$25.57 M(+12.6%) | -$92.44 M(+5.7%) |
| June 2010 | - | -$22.71 M(-3.7%) | -$87.42 M(+1.7%) |
| Mar 2010 | - | -$23.59 M(+14.6%) | -$85.95 M(+2.1%) |
| Dec 2009 | -$84.29 M(-2.3%) | -$20.59 M(+0.2%) | -$84.16 M(+4.9%) |
| Sept 2009 | - | -$20.54 M(-3.3%) | -$80.25 M(-2.8%) |
| June 2009 | - | -$21.24 M(-2.6%) | -$82.60 M(-3.6%) |
| Mar 2009 | - | -$21.80 M(+30.7%) | -$85.68 M(-0.7%) |
| Dec 2008 | -$86.26 M(+33.7%) | -$16.68 M(-27.2%) | -$86.26 M(+1.8%) |
| Sept 2008 | - | -$22.89 M(-5.9%) | -$84.77 M(+7.2%) |
| June 2008 | - | -$24.32 M(+8.7%) | -$79.10 M(+12.5%) |
| Mar 2008 | - | -$22.38 M(+47.4%) | -$70.28 M(+8.9%) |
| Dec 2007 | -$64.53 M(+46.6%) | -$15.18 M(-11.8%) | -$64.53 M(+5.2%) |
| Sept 2007 | - | -$17.22 M(+11.1%) | -$61.35 M(+13.3%) |
| June 2007 | - | -$15.50 M(-6.8%) | -$54.15 M(+2.9%) |
| Mar 2007 | - | -$16.63 M(+38.6%) | -$52.62 M(+19.5%) |
| Dec 2006 | -$44.03 M(+79.8%) | -$12.00 M(+19.7%) | -$44.03 M(+88.2%) |
| Sept 2006 | - | -$10.02 M(-28.3%) | -$23.39 M(-4.5%) |
| June 2006 | - | -$13.97 M(+73.8%) | -$24.50 M(+10.7%) |
| Mar 2006 | - | -$8.04 M(-193.0%) | -$22.13 M(-9.6%) |
| Dec 2005 | -$24.48 M(-29.2%) | $8.64 M(-177.7%) | -$24.48 M(-22.1%) |
| Sept 2005 | - | -$11.13 M(-4.1%) | -$31.41 M(+0.1%) |
| June 2005 | - | -$11.61 M(+11.7%) | -$31.39 M(-5.8%) |
| Mar 2005 | - | -$10.39 M(-707.4%) | -$33.32 M(-3.6%) |
| Dec 2004 | -$34.58 M(-15.8%) | $1.71 M(-115.4%) | -$34.58 M(-20.1%) |
| Sept 2004 | - | -$11.10 M(-18.0%) | -$43.28 M(+4.0%) |
| June 2004 | - | -$13.54 M(+16.2%) | -$41.63 M(+2.6%) |
| Mar 2004 | - | -$11.65 M(+66.8%) | -$40.56 M(-1.2%) |
| Dec 2003 | -$41.06 M(-3.0%) | -$6.99 M(-26.1%) | -$41.06 M(-5.0%) |
| Sept 2003 | - | -$9.45 M(-24.3%) | -$43.24 M(-6.0%) |
| June 2003 | - | -$12.48 M(+2.7%) | -$46.02 M(+4.4%) |
| Mar 2003 | - | -$12.15 M(+32.6%) | -$44.10 M(+4.2%) |
| Dec 2002 | -$42.31 M(+56.2%) | -$9.16 M(-25.1%) | -$42.31 M(+3.2%) |
| Sept 2002 | - | -$12.23 M(+15.9%) | -$41.00 M(+26.4%) |
| June 2002 | - | -$10.55 M(+1.8%) | -$32.43 M(+6.9%) |
| Mar 2002 | - | -$10.37 M(+32.0%) | -$30.33 M(+12.0%) |
| Dec 2001 | -$27.09 M(-17.6%) | -$7.85 M(+114.8%) | -$27.09 M(-9.9%) |
| Sept 2001 | - | -$3.66 M(-56.7%) | -$30.08 M(+9.1%) |
| June 2001 | - | -$8.45 M(+18.5%) | -$27.56 M(+27.7%) |
| Mar 2001 | - | -$7.13 M(-34.2%) | -$21.59 M(+39.9%) |
| Dec 2000 | -$32.86 M(+204.2%) | -$10.84 M(+851.6%) | -$15.43 M(+236.2%) |
| Sept 2000 | - | -$1.14 M(-54.0%) | -$4.59 M(+33.0%) |
| June 2000 | - | -$2.48 M(+153.9%) | -$3.45 M(+253.9%) |
| Mar 2000 | - | -$975.10 K | -$975.10 K |
| Dec 1999 | -$10.80 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual EBITDA year-on-year change?
- What is Lexicon Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Lexicon Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM EBITDA year-on-year change?
What is Lexicon Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of LXRX is -$163.46 M
What is the all time high annual EBITDA for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $148.45 M
What is Lexicon Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, LXRX annual earnings before interest, taxes, depreciation & amortization has changed by -$64.73 M (-65.55%)
What is Lexicon Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of LXRX is -$60.12 M
What is the all time high quarterly EBITDA for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $226.18 M
What is Lexicon Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, LXRX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$13.65 M (-29.37%)
What is Lexicon Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of LXRX is -$198.69 M
What is the all time high TTM EBITDA for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $182.81 M
What is Lexicon Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, LXRX TTM earnings before interest, taxes, depreciation & amortization has changed by -$50.13 M (-33.74%)